12:00 AM
May 24, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Results

IntraDose: Phase III

In two Phase III trials in the U.S. and Europe in 127 patients with breast or esophageal cancer, melanoma or other tumors, 45 percent of...

Read the full 103 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >